ATXN7L3

Across TCGA pan-cancer cohorts, ATXN7L3 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ATXN7L3 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher ATXN7L3 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ATXN7L3 expression acts as an unfavorable survival marker, although some lineages such as LUAD and LSCC show a favorable association.

LUAD, LSCC, and UCEC are the cancer types where ATXN7L3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Median	III,IV	0.732	0.220	.001	19	view →
LSCC	DFS	Median	All	0.998	0.873	.005	18	view →
UCEC	OS	Tertile	III,IV	0.807	0.483	.042	4	view →
HNSC	OS	Quartile	IV	0.924	0.510	.008	4	view →
GBM	OS	Quartile	All	0.391	0.634	.027	3	view →
PDAC	OS	Tertile	All	0.752	0.887	.017	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ATXN7L3–LUAD (DFS)

Open the LUAD breakdown →